CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene

Combines CREATE's multi-immune programming and RNA gene-writing platforms with WestGene's targeted LNP technology to support broad clinical proof of concept, including in China. Advances three next-generation in vivo CAR programs: dual-target CD19 × BCMA for autoimmune disease,...